DOCSLIB.ORG

Sleep and Comorbid Neurologic Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sleep and Comorbid Neurologic Disorders Review Article Address correspondence to Dr Nathaniel F. Watson, Harborview Medical Center, Sleep and Comorbid UW Medicine Sleep Center, 325 Ninth Ave, Box 359803, Seattle, WA, 98104, Neurologic Disorders [email protected]. Relationship Disclosure: Nathaniel F. Watson, MD, MSc; Mari Viola-Saltzman, DO Dr Watson serves on the Board of Directors for the American Academy of Sleep Medicine and the American ABSTRACT Sleep Medicine Foundation. Dr Viola-Saltzman reports no Purpose of Review: An understanding of the impact of sleep on neurologic disclosure. disorders, and the impact of neurologic disorders on sleep, provides fresh opportunities Unlabeled Use of for neurologists to improve the quality of life and functioning of their patients. Products/Investigational Recent Findings: Sleep-disordered breathing (SDB) is a risk factor for cerebrovascular Use Disclosure: Drs Watson and Viola-Saltzman report no disease and should be considered in all TIA and stroke patients. Sleep disorders can disclosures. amplify nociception and worsen headache disorders; and some headaches, including * 2013, American Academy those related to SDB and hypnic headache, are sleep specific. REM sleep behavior of Neurology. disorder may be an early sign of neurodegenerative disease. Focal lesions of almost any etiology (eg, multiple sclerosis and CNS malignancies) in the hypothalamus, basal forebrain, or brainstem may result in sleep disturbance, sleepiness, and insomnia. Sleep-related hypoventilation and fatigue are common in neuromuscular disease. SDB and epilepsy are mutually facilitatory, and poor sleep can exacerbate epilepsy. Summary: Continued surveillance for sleep disorders by neurologists is rewarded by new treatment avenues in their patients with the possibility of improved clinical outcomes. Continuum (Minneap Minn) 2013;19(1):148–169. INTRODUCTION increases incident stroke risk.2Y6 Even Sleep medicine is neurology; all sleep mild SDB is associated with increased 5 disorders emanate from or involve the incident stroke and increased risk of 6 central or peripheral nervous system. composite stroke, TIA, or death. The Even sleep-disordered breathing (SDB), reverse is also true: incident cardiovas- considered by many a pulmonary or cular disease is associated with worsen- 7 otolaryngologic disorder, is caused in ing of SDB over a 5-year period. large part by ineffective maintenance of Incident stroke in particular increases oropharyngeal muscle tone in sleep. The central SDB, which is common following intersection between sleep and neuro- stroke, and may represent silent brain logic disorders is broad and deep. Al- ischemia disturbing central respiratory Supplemental digital content: mechanisms.8 Table 8-1 presents a syn- Videos accompanying this ar- most every neurologic disorder affects ticle are cited in the text as or is affected by sleep. opsis of epidemiologic studies assessing Supplemental Digital Content. incident stroke in patients with SDB. Videos may be accessed by CEREBROVASCULAR DISEASE clicking on links provided in Stroke timing favors a role for SDB. the HTML, PDF, and iPad AND SLEEP-DISORDERED Awakening increases sympathetic versions of this article; the BREATHING URLs are provided in the print nervous system activity and the renin- version. Video legends begin Multiple well-adjusted, cross-sectional angiotensin-aldosterone axis, causing a on page 165. studies show a dose-response relation- sharp morning rise in arterial blood ship between sleep-disordered breath- pressure and heart rate. Both ischemic ing (SDB) severity and odds of prevalent and hemorrhagic stroke have a peak stroke.1,2 Longitudinal studies also dem- incidence in the morning hours, with onstrate that increased SDB severity ischemic stroke occurring about the time 148 www.aan.com/continuum February 2013 Copyright @ American Academy of Neurology. Unauthorized reproduction of this article is prohibited. TABLE 8-1 Synopsis of Studies Assessing Incident Stroke in Patients With Sleep-Disordered Breathing Number Time of Events Fully Adjusted Followed (Strokes) Odds Ratio or Study N = (Years) Observed Hazard Ratio P Value Comments Arzt2 1189 4 21 OR: 3.08 .120 Unadjusted OR: 4.31 (95% CI; 0.74Y12.81) (1.31Y14.15), P=.02 Munoz3 394 6 20 HR: 2.52 .040 HR presented for subjects (95% CI; 1.04Y6.01) with severe obstructive sleep apnea (apnea-hypopnea index [AHI] Q30 events/h) Redline4 5422 ~8 193 HR: 2.86 .016 Incident stroke was not (95% CI; 1.10Y7.40) associated with AHI quartiles in women HR presented for highest AHI quartile (919 events/h); P value is for trend Valham5 392 10 47 HR: 3.56 .011 HR presented for subjects (95% CI; 1.56Y8.16) with moderate to severe obstructive sleep apnea (AHI Q15 events/h); P value is for trend Yaggi6 1022 ~3 88 HR: 1.97 .010 Outcome was incident (95% CI; 1.12Y3.48) stroke and death OR = odds ratio; CI = confidence interval; HR = hazard ratio. mostpeoplearewakinguptostarttheir indices and lower mean oxygen sat- day.9 Interestingly, none of the more uration levels. The presence of severe common vascular risk factors or other sleep apnea (apnea-hypopnea index etiologic factors for stroke (including [AHI] greater than 30 events/h) was patient demographics, vascular distribu- independently associated with wake-up tion, ischemic heart disease, previous stroke.11 myocardial infarction, diabetes mellitus, During healthy nocturnal sleep, both hypertension, smoking, hyperlipidemia, systolic and diastolic blood pressures stroke severity and recurrence, stroke drop by 10% to 20% from respective subtype, and other clinical features) vary daytime mean levels. Some patients, in a statistically significant manner referred to as nondippers, have less than according to the clock time of stroke a 10% decline in blood pressure relative onset.10 The temporal pattern of stroke to respective daytime means. Nondip- points to the impact of circadian factors ping, over time, likely contributes to left on vascular tone, coagulative balance, ventricular hypertrophy, renal pathol- and blood pressure. Perhaps most com- ogy, and deleterious effects on brain pellingly, a case-control study compar- vasculature such as atheromatous nar- ing subjects with wake-up stroke to rowing or occlusion of larger cerebral those without wake-up stroke found vessels, thickening of cerebral arteries by the wake-up stroke group had higher lipohyalinosis, and increased blood co- apnea-hypopnea and obstructive apnea agulability. Nondipping blood pressure Continuum (Minneap Minn) 2013;19(1):148–169 www.aan.com/continuum 149 Copyright @ American Academy of Neurology. Unauthorized reproduction of this article is prohibited. Comorbid Neurologic Disorders KEY POINTS h pattern is associated with stroke inde- by approximately 1.5 mm Hg to 2.5 Sleep-disordered 12 breathing is a term that pendent of sex and race. Stroke risk is mm Hg and diastolic blood pressure by 16,17 encompasses all increased by 80% for every 5 mm Hg 1.5 mm Hg to 2.0 mm Hg. In 13 breathing disturbances increase in sleep-time blood pressure. another two meta-analyses reporting in sleep, including Obstructive sleep apnea (OSA) is one of changes in blood pressure obtained by obstructive sleep apnea, the most common causes of nondip- ambulatory monitoring, CPAP use was central sleep apnea, ping nocturnal blood pressure. associated with an approximately 1.0 Cheyne-Stokes The effect of SDB on blood pressure mmHgto1.5mmHgreductionin respirations, and upper is not confined only to the sleep period. both 24-hour systolic and diastolic blood airway resistance Approximately 50% to 60% of patients pressure.18,19 In subgroup analyses, syndrome. with OSA are hypertensive, while about severe OSA (more than 30 events per h Sleep-disordered 30% to 40% of hypertensive patients hour), higher blood pressure levels, and breathing is an have OSA.14 Peppard and colleagues15 greater CPAP adherence were associ- independent risk factor performed a 4-year, population-based, ated with larger reductions in blood for stroke. prospective cohort study of OSA and pressure.16Y19 hypertension. After adjusting for multi- ple confounders, they found that even Additional Obstructive Sleep people with few episodes of apnea or Apnea–Related Factors That hypopnea (0.1 events/h to 4.9 events/h) Increase Stroke Risk at baseline had 42% greater odds of OSA increases systemic sympathetic having hypertension at follow-up than nervous system activity and atrial size people with no episodes. They also (through left ventricular hypertrophy found those with mild SDB (AHI of 5.0 and increased transmural pressure), events/h to 14.9 events/h) and those which increases the risk of atrial fibrilla- with more severe SDB (AHI of 15.0 or tion, a major stroke risk factor.20 In ad- more events/h) had approximately 2 and dition, cardioverted atrial fibrillation is 3 times, respectively, the odds of having more likely to recur in untreated versus hypertension at follow-up than those treated OSA patients.21 Sleep disrup- with no episodes of apnea or hypo- tion and chronic intermittent hypoxia pnea.15 Resistant hypertension is defined in OSA increase oxidative stress and as blood pressure that requires four or vascular inflammation, which results in more antihypertensive medications. endothelial dysfunction characterized by Stunningly, 80% to 90% of these patients reduced vasodilatation and enhanced have OSA. Pathophysiologic mecha- vasoconstriction, including chronic pro- nisms include activation of the renin- thrombotic and procoagulant activity.22 angiotensin-aldosterone system by Apneas
Load more

Recommended publications
  • ON ATTRACTION of SLIME MOULD PHYSARUM POLYCEPHALUM to PLANTS with SEDATIVE PROPERTIES 1. Introduction Physarum Polycephalum Belo
    ON ATTRACTION OF SLIME MOULD PHYSARUM POLYCEPHALUM TO PLANTS WITH SEDATIVE PROPERTIES ANDREW ADAMATZKY Abstract. A plasmodium of acellular slime mould Physarum polycephalum is a large single cell with many nuclei. Presented to a configuration of attracting and repelling stimuli a plasmodium optimizes its growth pattern and spans the attractants, while avoiding repellents, with efficient network of protoplasmic tubes. Such behaviour is interpreted as computation and the plasmodium as an amorphous growing biologi- cal computer. Till recently laboratory prototypes of slime mould computing devices (Physarum machines) employed rolled oats and oat powder to represent input data. We explore alternative sources of chemo-attractants, which do not require a sophis- ticated laboratory synthesis. We show that plasmodium of P. polycephalum prefers sedative herbal tablets and dried plants to oat flakes and honey. In laboratory experi- ments we develop a hierarchy of slime-moulds chemo-tactic preferences. We show that Valerian root (Valeriana officinalis) is strongest chemo-attractant of P. polycephalum outperforming not only most common plants with sedative activities but also some herbal tablets. Keywords: Physarum polycephalum, slime mould, valerian, passion flower, hops, ver- vain, gentian, wild lettuce, chemo-attraction 1. Introduction Physarum polycephalum belongs to the species of order Physarales, subclass Myxo- gastromycetidae, class Myxomycetes, division Myxostelida. It is commonly known as a true, acellular or multi-headed slime mould. Plasmodium is a `vegetative' phase, single cell with a myriad of diploid nuclei. The plasmodium looks like an amorphous yellowish mass with networks of protoplasmic tubes. The plasmodium behaves and moves as a giant amoeba. It feeds on bacteria, spores and other microbial creatures and micro- particles (Stephenson & Stempen, 2000).
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Central Periodic Breathing During Sleep in 74 Patients with Acute Ischemic Stroke - Neurogenic and Cardiogenic Factors
    Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L (2008). Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors. Journal of Neurology, 255(11):1687-1692. Postprint available at: http://www.zora.uzh.ch University of Zurich Posted at the Zurich Open Repository and Archive, University of Zurich. Zurich Open Repository and Archive http://www.zora.uzh.ch Originally published at: Journal of Neurology 2008, 255(11):1687-1692. Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L (2008). Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors. Journal of Neurology, 255(11):1687-1692. Postprint available at: http://www.zora.uzh.ch Posted at the Zurich Open Repository and Archive, University of Zurich. http://www.zora.uzh.ch Originally published at: Journal of Neurology 2008, 255(11):1687-1692. CENTRAL PERIODIC BREATHING IN 74 PATIENTS WITH ACUTE ISCHEMIC STROKE - NEUROGENIC VERSUS CARDIOGENIC FACTORS Massimiliano M. Siccoli, MD Philipp O. Valko, MD Dirk M. Hermann, MD Claudio L. Bassetti, MD Department of Neurology, University Hospital of Zurich, Switzerland Correspondence: Prof. Claudio L. Bassetti Department of Neurology University Hospital of Zurich Frauenklinikstrasse 26
    [Show full text]
  • Sleep Apnea Sleep Apnea
    Health and Safety Guidelines 1 Sleep Apnea Sleep Apnea Normally while sleeping, air is moved at a regular rhythm through the throat and in and out the lungs. When someone has sleep apnea, air movement becomes decreased or stops altogether. Sleep apnea can affect long term health. Types of sleep apnea: 1. Obstructive sleep apnea (narrowing or closure of the throat during sleep) which is seen most commonly, and, 2. Central sleep apnea (the brain is causing a change in breathing control and rhythm) Obstructive sleep apnea (OSA) About 25% of all adults are at risk for sleep apnea of some degree. Men are more commonly affected than women. Other risk factors include: 1. Middle and older age 2. Being overweight 3. Having a small mouth and throat Down syndrome Because of soft tissue and skeletal alterations that lead to upper airway obstruction, people with Down syndrome have an increased risk of obstructive sleep apnea. Statistics show that obstructive sleep apnea occurs in at least 30 to 75% of people with Down syndrome, including those who are not obese. In over half of person’s with Down syndrome whose parents reported no sleep problems, sleep studies showed abnormal results. Sleep apnea causing lowered oxygen levels often contributes to mental impairment. How does obstructive sleep apnea occur? The throat is surrounded by muscles that are active controlling the airway during talking, swallowing and breathing. During sleep, these muscles are much less active. They can fall back into the throat, causing narrowing. In most people this doesn’t affect breathing. However in some the narrowing can cause snoring.
    [Show full text]
  • Receives Fda Approval for the Treatment of Insomnia
    AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED-RELEASE TABLETS) CIV RECEIVES FDA APPROVAL FOR THE TREATMENT OF INSOMNIA First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population Paris, France, September 6, 2005 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number ® one prescription sleep aid, AMBIEN (zolpidem tartrate) CIV, for the treatment of insomnia. AMBIEN CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to AMBIEN with a new indication for sleep maintenance, in addition to sleep induction. AMBIEN CR is the first and only extended-release prescription sleep medication to help people with insomnia fall asleep fast and maintain sleep with no significant decrease in next day performance. AMBIEN CR, a bi-layered tablet, is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep. “Insomnia is a significant public health problem, affecting millions of Americans. Insomnia impacts daily activities and is associated with increased health care costs,” said James K. Walsh, PhD, Executive Director and Senior Scientist, Sleep Medicine and Research Center at St. Luke's Hospital in St. Louis, Missouri. “Helping patients stay asleep is recognized as being as important as helping them fall asleep,” said Walsh. “Ambien CR has shown evidence of promoting sleep onset and more continuous sleep".
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Respiratory Assist Device Appendices a and B
    DRAFT Appendix A Clinical Indications for the Use of Respiratory Assist Device (RAD) Therapy Indications for use of a RAD is divided into four categories: • Restrictive thoracic disorders, e.g., neuromuscular disorders such as amyotrophic lateral sclerosis; • Severe chronic obstructive pulmonary disease (COPD); o Use of a RAD in COPD patients requires, . A facility-based polysomnogram to rule out obstructive sleep apnea in order to initiate Medicare coverage, . A prerequisite trial of noninvasive ventilation without a backup rate, and . Treatment with continuous positive airway pressure devices. • Central sleep apnea, i.e., apnea not due to airway obstruction; and • Obstructive sleep apnea (OSA). Initial Coverage (First 3 Months of Therapy) Medical record must document symptoms characteristic of sleep-associated hypoventilation, e.g.: • Daytime hypersomnolence; • Excessive fatigue; • Morning headache; • Cognitive dysfunction; • Dyspnea, etc.; and • Beneficiary has one (1) of the disorders listed in the Documentation Verification Procedures section below and meets all coverage criteria for that disorder. Continued Coverage (Beyond First 3 Months of Therapy) - E0470 or E0471 Medical records document the beneficiary was re-evaluated on/after the 61st day of therapy demonstrating: • Progress of relevant symptoms; and • Beneficiary usage of the device (average 4 hours per 24 hours) Documentation in supplier’s records includes the following: • Signed and dated physician statement completed no sooner than 61 days after initiating use of the
    [Show full text]
  • Principles of Practice Parameters for The
    ERJ Express. Published on July 28, 2016 as doi: 10.1183/13993003.01975-2015 TASK FORCE REPORT IN PRESS | CORRECTED PROOF Principles of practice parameters for the treatment of sleep disordered breathing in the elderly and frail elderly: the consensus of the International Geriatric Sleep Medicine Task Force Nikolaus C. Netzer (Chair)1,2, Sonia Ancoli-Israel (Co-chair)3, Donald L. Bliwise4, Stephany Fulda5, Christine Roffe6, Fernanda Almeida7, Hakki Onen8, Fannie Onen9, Friedhart Raschke10, Miguel Angel Martinez Garcia11 and Helmut Frohnhofen12 Affiliations: 1Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Dept of Sports Science, Faculty of Psychology and Sports Science, University Innsbruck, Austria. 2Division of Sports Medicine and Rehabilitation, Dept of Medicine, University Hospitals Ulm, Ulm, Germany. 3Depts of Psychiatry and Medicine, University of California, San Diego, CA, USA. 4Sleep Program, Dept of Neurology, Emory University, Atlanta, GA, USA. 5Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Lugano, Switzerland. 6Institute for Science and Technology in Medicine, Keele University, Keele, UK. 7Dental Medical School, University of British Colombia, Vancouver, BC, Canada. 8Geriatric Sleep Center, Edouard Herriot University Hospital, HCL, Lyon, France. 9Dept of Geriatrics, Bichat University Hospital, APHP and INSERM U669, Paris, France. 10Institute for Rehabiltation Research, Hospital Norderney, Norderney, Germany. 11Respiratory Dept, La Fe University and Polytechnic Hospital, Valencia, Spain. 12Dept of Geriatric Medicine, Kliniken Essen Mitte, Essen, Germany. Correspondence: Nikolaus C Netzer, Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Ghersburg Clinic for Geriatric Rehabilitation, Ghersburgstr. 9, 83043 Bad Aibling, Germany. Email: [email protected] ABSTRACT Sleep disordered breathing (SDB) is a leading cause of morbidity worldwide.
    [Show full text]
  • Insomnia in the Elderly: Update on Assessment and Management
    To see other CME articles, go to: www.cmegeriatrics.ca www.geriatricsjournal.ca If you are interested in receiving this publication on a regular basis, please consider becoming a member. INSOMNIA IN THE ELDERLY: UPDATE ON ASSESSMENT AND MANAGEMENT Canadian Geriatrics Society Abstract Insomnia disorder is one of the most common sleep-wake disorders seen Soojin Chun in the geriatric population, and is associated with multiple psychiatric MSc., MD FRCP(C) and medical consequences. Insomnia is a subjective complaint of Geriatric Psychiatry difficulty falling and/or staying asleep, or experiencing non-restorative Subspecialty Resident sleep, associated with significant daytime consequences including (PGY-6), University of difficulty concentrating, fatigue and mood disturbances. There is no Ottawa single diagnostic tool to assess insomnia. Consequently, an insomnia assessment requires thorough history taking including a sleep inquiry, Elliott Kyung Lee medical history, psychiatric history, substance use history and a relevant MD, FRCP(C), D. ABPN physical examination. Insomnia is often multifactorial in origin, and Sleep Med, Addiction routinely is associated with multiple other psychiatric and medical Psych, D. ABSM, F. AASM, disorders. Therefore, predisposing, precipitating and perpetuating factors F. APA, Sleep Specialist, must be carefully examined in the context of an evaluation of insomnia Royal Ottawa Mental symptoms. Other specific sleep assessments (e.g., overnight Health Centre, Assistant polysomnography) can be completed to rule out other sleep-wake Professor, University of disorders. For management, a cognitive-behavioural approach (including Ottawa sleep restriction therapy, stimulus control therapy) is commonly accepted as an effective, first-line treatment for insomnia disorder. Corresponding Author: A brief version of CBT-I focusing on behavioural interventions (Brief Elliott Kyung Lee Behavioural Treatment of Insomnia, BBT-I) has also demonstrated efficacy in the geriatric patient population.
    [Show full text]
  • Sleep Apnea and the Brain: Neurocognitive and Emotional Considerations
    Vitale et al. J Sleep Disord Manag 2016, 2:008 Volume 2 | Issue 1 Journal of Sleep Disorders and Management Review Article: Open Access Sleep Apnea and the Brain: Neurocognitive and Emotional Considerations Gregory John Vitale*, Kimberly Capp, Kimberly Ethridge, Maggie S. Lorenzetti, Mary Jef- frey, John Skicki and Ashley Stripling College of Psychology, Nova Southeastern University, Florida, USA *Corresponding author: Gregory John Vitale, College of Psychology, Nova Southeastern University, 3301 College Ave., Fort Lauderdale, Florida, 33314, USA, Tel: 9548298479, E-mail: [email protected] by utilizing a sleep diagnosis tool, called a polysomnography, to rule Abstract out other sleep disturbances and determine an individual’s apnea- Sleep apnea research has become increasingly relevant to the hypopnea index (AHI). The AHI is based on the number of apnea/ field of psychology. Although the physiological sequelae have hypopnea episodes that occur during a one-hour period of sleep been researched extensively, and treatment options are now and is used to indicate severity of the disorder. An AHI above 5 available for those diagnosed, much is left to be done. Specifically, but less than 15 is considered to be in the mild and impacts 3-28% to date, the cognitive and psychological consequences of sleep apnea have received less attention. As such, this paper serves of individuals, while an AHI above 15 is considered moderate and to review the current state of the literature and presents relevant impacts 1-14% of individuals [1]. Cases of 30 or more episodes per neuropsychological and emotional domains. Given that sleep hour are considered severe and are almost always associated with apnea may cause psychological dysfunction over-and-above those intensified sequelae (e.g.
    [Show full text]
  • A Acetylcholine Anticholinergic Drugs, 49 Cholinergic Wake-Promoting
    Index A C Acetylcholine Cataplexy anticholinergic drugs, 49 GHB, 37 cholinergic wake-promoting system, 48 narcolepsy type 1, 215 cholinesterase inhibitors, 48–49 narcolepsy type 2, 215 milameline, 49 sleep-promoting orexinergic inhibitors, 46 nicotine, 49 SXB, 238–240 receptors, 48 tricyclic antidepressants, 253 sleep-promoting cholinergic Cell replacement therapy, 253 inhibitors, 49 Central sleep apnea (CSA) syndrome, 76 Adenosine Cheyne–Stokes breathing (CSB), 76 adenosine-mediated sleep-promoting Cholinesterase inhibitors system, 41 donepezil, 49 receptors, 42 physostigmine, 48 sleep-promoting adenosine receptor Chronic insomnia agonists, 42 dose discrimination, lack of, 168 wake-promoting adenosine receptor psychiatric comorbidities, 169 antagonists, 42 short-term efficacy and long-term safety, Amantadine, 77 167–168 Armodafinil sleep induction and maintenance, 168–169 chemical structure, 212 Chronic obstructive sleep apnea multiple sclerosis, 222 (OSA), 178–179 narcolepsy, 218 Chronic primary insomnia obstructive sleep apnea, 219–221 adverse effects, 165, 167 pharmacokinetics, 214 comorbid psychiatric disorders, 164 R enantiomer, 213 double-blind trial, 164 safety, 224–225 efficacy, 165 shift work disorder, 223 long-term trial, 165 open-label extension phase, 165 post hoc analysis, 165–166 B psychomotor performance, 164–165 Benzodiazepine Withdrawal Symptom rebound insomnia, 164 Questionnaire (BWSQ), 183 WASO, 164–165 © Springer International Publishing Switzerland 2015 289 A. Guglietta (ed.), Drug Treatment of Sleep Disorders, Milestones
    [Show full text]
  • Antibiotic-Induced Depletion of the Gut Microbiota Reduces Nocturnal Sleep in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/199075; this version posted October 5, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Sleep and the gut microbiome: antibiotic-induced depletion of the gut microbiota reduces nocturnal sleep in mice Jonathan Lendrum1, a, *, Bradley Seebach1, Barrett Klein1, Sumei Liu1 1Department of Biology, University of Wisconsin – La Crosse, 1725 State St, La Crosse, WI 54601, USA aCorrespondence (J. Lendrum): Tel: +1(920)-850-7883. E-mail: [email protected] *Permanent Address (J. Lendrum): 5600 11th Ave S, Minneapolis, MN 55417, USA Highlights -14 d broad-spectrum antibiotic treatment effectively depletes the gut microbiota. -Gut microbiota depletion reduces nocturnal sleep, but not diurnal sleep. -Gut microbiota depletion increases nocturnal locomotion, but not diurnal locomotion. -Antibiotics may be insomnogenic: implications for idiopathic sleep disorders. Abstract Several bacterial cell wall components such as peptidoglycan and muramyl peptide are potent inducers of mammalian slow-wave sleep when exogenously administered to freely behaving animals. It has been proposed that the native gut microflora may serve as a quasi-endogenous pool of somnogenic bacterial cell wall products given their quantity and close proximity to the intestinal portal. This proposal suggests that deliberate manipulation of the host’s intestinal flora may elicit changes in host sleep behavior. To test this possibility, we evaluated 24 h of sleep-wake behavior after depleting the gut microbiota with a 14 d broad-spectrum antibiotic regimen containing high doses of ampicillin, metronidazole, neomycin, and vancomycin.
    [Show full text]